Method for determining active SARS-CoV-2-infections
AssigneeCeinge Biotecnologie Avanzate Franco Salvatore S.C. A R.L.
InventorsEttore Domenico Capoluongo, Veronica Ferrucci, Massimo Zollo
Life of this patent
Estimating the term…
Abstract
Method for early determination of an active SARS-CoV2 infection, based on identification of subgenomic regions of the virus, and kits specifically designed for performing it.
Claims13
An in vitro method for determining the presence of active SARS-CoV2 infection in a subject, wherein said infection is at an early stage and is characterised by a high viral load, said method comprising detecting viral subgenomic RNA encoding the nucleoprotein N (sgN) and viral subgenomic RNA encoding the envelope protein (sgE) in a biological cell or tissue sample from the subject.
An in vitro method for predicting viral negativization after SARS-CoV2 infection in a patient, said method comprising determining the levels of sgN and sgE RNAs in a biological sample from said patient at different times from SARS-CoV2 infection detection, wherein a decreased expression of sgN over time or the loss of sgN detection while the sgE detection levels remain unchanged, indicates benign SARS-CoV-2 negativization in said patient.
Dependencies are inferred from the claim text.